• AMD-070 Hydrochloride CXCR4 Assay Workflows

  2026-09-09

  Build mechanism-led migration, immune-cell, and translational assays with AMD-070 hydrochloride, a selective CXCR4 antagonist for probing CXCR4/CXCL12 biology. This workflow emphasizes genotype-aware Waldenström macroglobulinemia models, assay controls, and carefully bounded anti-HIV research applications rather than unsupported clinical extrapolation.

• Lypressin Acetate: An Assay Decision Framework

  2026-09-09

  Lypressin acetate is a multifunctional vasopressin analog for receptor, antidiuretic, and vasoconstriction research. This article presents an assay-centered framework for separating receptor pharmacology, bioassay potency, and exploratory SARS-CoV-2 RdRp studies.

• Aconitase Activity Colorimetric Assay Kit Guide

  2026-09-08

  Learn how Aconitase Activity Colorimetric Assay Kit, SKU K2226, can complement viability and cytotoxicity studies by quantifying aconitase activity and oxidative metabolic injury. This scenario-based guide covers assay principles, sample compatibility, protocol controls, interpretation, and practical product selection.

• Etomoxir: CPT-1 Inhibition in Immunometabolism

  2026-09-08

  Etomoxir, also called R-(+)-Etomoxir in research contexts, is a cell-permeable, irreversible CPT-1 inhibitor used to interrogate fatty acid oxidation. Its DGAT activity and model-dependent effects require dose-aware controls in fatty acid oxidation pathway research and immunometabolic assays.

• Candida auris Antifungal Pipeline: Systematic Review

  2026-09-07

  This systematic review maps the preclinical antifungal pipeline for multidrug-resistant Candida auris, integrating susceptibility data with evidence from animal candidemia models. Its main practical contribution is a structured comparison of emerging drug classes while highlighting the assay heterogeneity and limited clinical evidence that constrain translation.

• Necrostatin-1 Workflows for Necroptosis Research

  2026-09-07

  Necrostatin-1 provides a mechanism-focused way to test whether RIP1 kinase signaling contributes to inflammatory or injury-associated cell death. This guide combines practical Nec-1 assay design with insights from nanospike-induced lysosomal stress, helping researchers distinguish necroptosis from autophagic cell death rather than relying on viability measurements alone.

• IWR-1-endo: A Context-Aware Wnt Assay Strategy

  2026-09-05

  IWR-1-endo is a mechanistically defined Wnt signaling inhibitor for interrogating β-catenin-dependent biology in colorectal cancer research and regenerative models. This guide combines pathway pharmacology with single-nucleus assay logic to improve cell-context resolution, endpoint selection, and experimental interpretation.

• Aclacinomycin A: Mechanism and Research Uses

  2026-09-04

  Aclacinomycin A, also called Aclarubicin, is an anthracycline DNA damage inducer with reported dual topoisomerase I and II inhibition. Product information reports apoptosis-associated caspase activation, proteasome chymotrypsin-like activity inhibition, and cell-line cytotoxicity values, while the cited rDNA study provides a framework for interpreting topological-stress responses: https://www.apexbt.com/aclacinomycin-a.html and https://doi.org/10.7554/eLife.91304.

• AMD-070 hydrochloride: CXCR4 Assay Workflows

  2026-09-04

  AMD-070 hydrochloride provides a soluble, selective way to interrogate CXCR4/CXCL12 biology in migration, immune-cell trafficking, hematologic, and anti-HIV research. This guide combines practical assay design with a cautious cross-domain lesson from an ischemia–reperfusion injury study.

• SERCA–ER Stress and HSC Mobilization

  2026-09-03

  Li et al. identify SERCA-mediated endoplasmic reticulum stress as a regulator of hematopoietic stem cell mobilization. Using BHQ, in vivo mobilization assays, cell-line knockdown, flow cytometry, qRT-PCR, and western blotting, the study links SERCA inhibition to the CaMKII–STAT3–CXCR4 pathway and reduced CXCR4 surface expression.

• Lypressin Acetate: Mechanism and Research Use

  2026-09-03

  Lypressin acetate, also called Lysine vasopressin acetate, is a lysine-substituted vasopressin peptide that activates V1a, V1b, and V2 receptors. Its established context is antidiuretic therapy and vasopressin research, while its SARS-CoV-2 RdRp activity remains an early translational hypothesis rather than a validated antiviral indication.

• Regorafenib Workflows for Angiogenesis Research

  2026-09-02

  Regorafenib (BAY 73-4506) supports integrated studies of kinase signaling, endothelial behavior, tumor-cell invasion, and melanoma mechanism. This practical guide connects dose-finding and migration assays with RRM2–ERK/E2F3 readouts for more interpretable cancer biology research.

• Sulfo-NHS-LC-Biotin Protocol and QC Guide

  2026-09-02

  Sulfo-NHS-LC-Biotin (SKU A8003) provides water-compatible, irreversible biotin labeling of accessible primary amines on proteins, peptides, and intact cell surfaces. It is suited to stable cell-surface protein biotinylation and streptavidin-based capture, but not to reversible modification or routine intracellular labeling.

• Sunitinib Workflows for RTK and RCC Research

  2026-09-01

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor for dissecting angiogenesis, tumor-cell survival, and resistance in advanced cancer models. This workflow-focused guide connects RTK pharmacology with metabolic rescue experiments, helping researchers distinguish direct pathway inhibition from glycolysis-driven treatment escape.

• ATRX Loss Increases Glioma Sensitivity to PDGFR Inhibitors

  2026-09-01

  The reference study shows that ATRX-deficient high-grade glioma cells are preferentially vulnerable to several receptor tyrosine kinase and PDGFR inhibitors, and that combining these agents with temozolomide can intensify cellular toxicity. Its main translational contribution is a genotype-aware framework for interpreting RTK inhibitor responses and designing glioma trials around ATRX status.

7955 records 2/531 page Previous Next 12345 下5页 Last page